Insmed is a biopharmaceutical company focused on serious and rare diseases, especially pulmonary conditions. Its commercial product ARIKAYCE (amikacin liposome inhalation suspension) treats refractory Mycobacterium avium complex lung disease. The pipeline targets additional respiratory and rare-disease indications, building on inhaled and specialty drug platforms. Customers are specialist physicians and health systems treating patients with limited alternative therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 107.4 | — | -321.7 | — |
| Q3 2025 | 142.3 | — | -370 | — |
| Q4 2025 | 263.8 | — | -328.5 | — |
| Q1 2026 | 306 | — | -163.6 | — |
| Q2 2026 | 425.5 | 296.1% | -13.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: PTC Inc. (PTC), Formula One Group (FWONA), Super Micro Computer, Inc. (SMCI), Royal Gold, Inc. (RGLD), MACOM Technology Solutions Holdings, Inc. (MTSI), SBA Communications Corporation (SBAC)